Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Colon cancer is the second leading cause of cancer deaths in the U.S., and a new study shows it may also raise the risk of ...